Title

Transcranial Direct Current Stimulation: Pre-Clinical

School Name

Academic Magnet High School

Grade Level

12th Grade

Presentation Topic

Physiology and Health

Presentation Type

Mentored

Abstract

In the United States, brain and nervous system tumors affect about 30 out of 100,000 adults. Brain tumors are dangerous because they can put pressure on healthy parts of the brain or spread into those areas. Brain tumors often are cancerous or become cancerous. Problems mainly occur when they block the flow of fluid around the brain, which can lead to an increase in pressure inside the skull. With current methods of encountering brain tumors such as radiation therapy the drawbacks can be dire if not fatal. A new treatment regarding low-cost, portable (battery-operated), painless, and low-intensity non-invasive transcranial direct current stimulation (tDCS) is not FDA-approved however it could be critical in providing an alternate and efficient method to hinder the drastic effects of brain tumors. Without a thorough study and pre-clinical data, we are not able to assess its viability for the future. By actively facilitating tDCS with a brain tumor investigated initiated drug (BTIID) with 30-60 minute treatments, we can assume that it will affect cellular composition and the root of the immunosuppressive tumor environment. The study exhibited without the BTIID it significantly decreased the protein levels of urokinase-type plasminogen activator receptor (uPAR) as well as phosphorylation of Akt and upregulates Bax expression. This shows its viability for the future of suppressing brain tumors and hopefully give evidence to lead to its access and FDA-approval.

Location

HSS 203

Start Date

4-2-2022 9:00 AM

Presentation Format

Oral Only

Group Project

No

COinS
 
Apr 2nd, 9:00 AM

Transcranial Direct Current Stimulation: Pre-Clinical

HSS 203

In the United States, brain and nervous system tumors affect about 30 out of 100,000 adults. Brain tumors are dangerous because they can put pressure on healthy parts of the brain or spread into those areas. Brain tumors often are cancerous or become cancerous. Problems mainly occur when they block the flow of fluid around the brain, which can lead to an increase in pressure inside the skull. With current methods of encountering brain tumors such as radiation therapy the drawbacks can be dire if not fatal. A new treatment regarding low-cost, portable (battery-operated), painless, and low-intensity non-invasive transcranial direct current stimulation (tDCS) is not FDA-approved however it could be critical in providing an alternate and efficient method to hinder the drastic effects of brain tumors. Without a thorough study and pre-clinical data, we are not able to assess its viability for the future. By actively facilitating tDCS with a brain tumor investigated initiated drug (BTIID) with 30-60 minute treatments, we can assume that it will affect cellular composition and the root of the immunosuppressive tumor environment. The study exhibited without the BTIID it significantly decreased the protein levels of urokinase-type plasminogen activator receptor (uPAR) as well as phosphorylation of Akt and upregulates Bax expression. This shows its viability for the future of suppressing brain tumors and hopefully give evidence to lead to its access and FDA-approval.